Literature DB >> 26964999

Acute and long-term effect of percutaneous coronary intervention on serially-measured oxidative, inflammatory, and coagulation biomarkers in patients with stable angina.

Gregor Leibundgut1,2, Jun-Hee Lee3, Bradley H Strauss4,5, Amit Segev6, Sotirios Tsimikas7.   

Abstract

To derive insights into the temporal changes in oxidative, inflammatory and coagulation biomarkers in patients with stable angina undergoing percutaneous coronary intervention (PCI). PCI is associated with a variety of biochemical and mechanical stresses to the vessel wall. Oxidized phospholipids are present on plasminogen (OxPL-PLG) and potentiate fibrinolysis in vitro. We recently showed that OxPL-PLG increase following acute myocardial infarction, suggesting that they are involved in atherothrombosis. Plasma samples were collected before, immediately after, 6 and 24 h, 3 and 7 days, and 1, 3, and 6 months after PCI in 125 patients with stable angina undergoing uncomplicated PCI. Plasminogen levels, OxPL-PLG, and an array of 16 oxidative, inflammatory and coagulation biomarkers were measured with established assays. OxPL-PLG and plasminogen declined significantly immediately post-PCI, rebounded to baseline, peaked at 3 days and slowly returned to baseline by 6 months (p < 0.0001 by ANOVA). The temporal trends to maximal peak in biomarkers were as follows: immediately post PCI: OxPL-apoB and lipoprotein (a); Day 1-the inflammatory biomarker IL-6; Day 3-CRP and coagulation biomarkers OxPL-PLG, plasminogen and tissue plasminogen activity; Day 3 to 7-plasminogen activator inhibitor activity, and complement factor H binding to malondialdehyde-LDL and MDA-LDL IgG; Day 7-30 MDA-LDL IgM, CuOxLDL IgM, and ApoB-IC IgM and IgG; >30 days uPA activity, uPA antigen, CuOxLDL IgG and peptide mimotope to MDA-LDL. Most of the biomarkers trended to baseline by 6 months. PCI results in a specific, temporal sequence of changes in plasma biomarkers. These observations provide insights into the effects of iatrogenic barotrauma and plaque disruption during PCI and suggest avenues of investigation to explain complications of PCI and development of targeted therapies to enhance procedural success.

Entities:  

Keywords:  Coagulation and oxidative biomarkers; Complement factor H; Oxidized phospholipids; Percutaneous coronary intervention; Plasminogen

Mesh:

Substances:

Year:  2016        PMID: 26964999      PMCID: PMC4811750          DOI: 10.1007/s11239-016-1351-6

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  46 in total

1.  The role of oxidized phospholipids, lipoprotein (a) and biomarkers of oxidized lipoproteins in chronically occluded coronary arteries in sudden cardiac death and following successful percutaneous revascularization.

Authors:  Paul Fefer; Sotirios Tsimikas; Amit Segev; John Sparkes; Fumiyuki Otsuka; Fumiyuki Otsuma; Frank Kolodgie; Renu Virmani; Joseph Juliano; Thierry Charron; Bradley H Strauss
Journal:  Cardiovasc Revasc Med       Date:  2011-11-13

Review 2.  The role of complement Factor H in age-related macular degeneration: a review.

Authors:  Larry A Donoso; Tamara Vrabec; Helena Kuivaniemi
Journal:  Surv Ophthalmol       Date:  2010 May-Jun       Impact factor: 6.048

Review 3.  Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events.

Authors:  Adam Taleb; Joseph L Witztum; Sotirios Tsimikas
Journal:  Biomark Med       Date:  2011-10       Impact factor: 2.851

Review 4.  Coronary microembolization: from bedside to bench and back to bedside.

Authors:  Gerd Heusch; Petra Kleinbongard; Dirk Böse; Bodo Levkau; Michael Haude; Rainer Schulz; Raimund Erbel
Journal:  Circulation       Date:  2009-11-03       Impact factor: 29.690

5.  Human oxidation-specific antibodies reduce foam cell formation and atherosclerosis progression.

Authors:  Sotirios Tsimikas; Atsushi Miyanohara; Karsten Hartvigsen; Esther Merki; Peter X Shaw; Meng-Yun Chou; Jennifer Pattison; Michael Torzewski; Janina Sollors; Theodore Friedmann; N Chin Lai; H Kirk Hammond; Godfrey S Getz; Catherine A Reardon; Andrew C Li; Carole L Banka; Joseph L Witztum
Journal:  J Am Coll Cardiol       Date:  2011-10-11       Impact factor: 24.094

6.  In vivo visualization and attenuation of oxidized lipid accumulation in hypercholesterolemic zebrafish.

Authors:  Longhou Fang; Simone R Green; Ji Sun Baek; Sang-Hak Lee; Felix Ellett; Elena Deer; Graham J Lieschke; Joseph L Witztum; Sotirios Tsimikas; Yury I Miller
Journal:  J Clin Invest       Date:  2011-11-21       Impact factor: 14.808

7.  Complement factor H binds malondialdehyde epitopes and protects from oxidative stress.

Authors:  David Weismann; Karsten Hartvigsen; Nadine Lauer; Keiryn L Bennett; Hendrik P N Scholl; Peter Charbel Issa; Marisol Cano; Hubert Brandstätter; Sotirios Tsimikas; Christine Skerka; Giulio Superti-Furga; James T Handa; Peter F Zipfel; Joseph L Witztum; Christoph J Binder
Journal:  Nature       Date:  2011-10-05       Impact factor: 49.962

8.  Oxidized phospholipids are present on plasminogen, affect fibrinolysis, and increase following acute myocardial infarction.

Authors:  Gregor Leibundgut; Kiyohito Arai; Alexina Orsoni; Huiyong Yin; Corey Scipione; Elizabeth R Miller; Marlys L Koschinsky; M John Chapman; Joseph L Witztum; Sotirios Tsimikas
Journal:  J Am Coll Cardiol       Date:  2012-04-17       Impact factor: 24.094

9.  Genetic variation in complement factor H and risk of coronary heart disease: eight new studies and a meta-analysis of around 48,000 individuals.

Authors:  Reecha Sofat; Juan P Casas; Meena Kumari; Philippa J Talmud; Helen Ireland; Mika Kivimaki; Michael Marmot; Alun D Hughes; Simon Thom; Shah Ebrahim; John C Whittaker; Liam Smeeth; Debbie A Lawlor; Steve E Humphries; Aroon D Hingorani
Journal:  Atherosclerosis       Date:  2010-07-29       Impact factor: 5.162

10.  Peptide mimotopes of malondialdehyde epitopes for clinical applications in cardiovascular disease.

Authors:  Shahzada Amir; Karsten Hartvigsen; Ayelet Gonen; Gregor Leibundgut; Xuchu Que; Erika Jensen-Jarolim; Oswald Wagner; Sotirios Tsimikas; Joseph L Witztum; Christoph J Binder
Journal:  J Lipid Res       Date:  2012-04-16       Impact factor: 5.922

View more
  4 in total

1.  In search of a physiological function of lipoprotein(a): causality of elevated Lp(a) levels and reduced incidence of type 2 diabetes.

Authors:  Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2018-04-02       Impact factor: 5.922

2.  Vascular Endothelial Cells Produce Coagulation Factors That Control Their Growth via Joint Protease-Activated Receptor and C5a Receptor 1 (CD88) Signaling.

Authors:  Devin Cao; Michael G Strainic; Daniel Counihan; Shiva Sridar; Fengqi An; Wasim Hussain; Alvin H Schmaier; Marvin Nieman; M Edward Medof
Journal:  Am J Pathol       Date:  2022-02       Impact factor: 4.307

3.  Association of D-dimer with Plaque Characteristics and Plasma Biomarkers of Oxidation-Specific Epitopes in Stable Subjects with Coronary Artery Disease.

Authors:  Hema Kothari; Anh T Nguyen; Xiaohong Yang; Yohei Hisada; Sotirios Tsimikas; Nigel Mackman; Angela Taylor; Coleen A McNamara
Journal:  J Cardiovasc Transl Res       Date:  2018-01-17       Impact factor: 4.132

4.  The Placebo-Controlled Effect of Percutaneous Coronary Intervention on Exercise Induced Changes in Anti-Malondialdehyde-LDL Antibody Levels in Stable Coronary Artery Disease: A Substudy of the ORBITA Trial.

Authors:  Adam Hartley; Matthew Shun-Shin; Mikhail Caga-Anan; Christopher Rajkumar; Alexandra N Nowbar; Michael Foley; Darrel P Francis; Dorian O Haskard; Ramzi Y Khamis; Rasha K Al-Lamee
Journal:  Front Cardiovasc Med       Date:  2021-10-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.